Cantor Fitzgerald Comments on ACRS FY2025 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Aclaris Therapeutics in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the biotechnology company will post earnings per share of ($0.54) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.81) per share.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. The company had revenue of $4.35 million for the quarter, compared to analyst estimates of $8.31 million.

A number of other research firms also recently weighed in on ACRS. HC Wainwright raised Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 target price for the company in a report on Monday, December 23rd. Piper Sandler upgraded shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $3.00 to $13.00 in a research note on Monday, November 18th. Leerink Partners raised shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $2.00 to $7.00 in a report on Tuesday, November 19th. Jefferies Financial Group raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and raised their target price for the stock from $2.00 to $7.00 in a report on Tuesday, November 19th. Finally, StockNews.com upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $11.00.

Aclaris Therapeutics Stock Performance

NASDAQ:ACRS opened at $2.60 on Wednesday. The stock has a 50 day simple moving average of $3.09 and a 200 day simple moving average of $1.96. The stock has a market cap of $185.72 million, a P/E ratio of -5.00 and a beta of 0.54. Aclaris Therapeutics has a 1-year low of $0.95 and a 1-year high of $5.17.

Institutional Investors Weigh In On Aclaris Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ACRS. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Aclaris Therapeutics by 187.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 332,406 shares of the biotechnology company’s stock valued at $382,000 after purchasing an additional 216,826 shares during the last quarter. BML Capital Management LLC increased its holdings in shares of Aclaris Therapeutics by 9.7% during the third quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company’s stock worth $16,388,000 after buying an additional 1,261,866 shares in the last quarter. Stonepine Capital Management LLC bought a new position in shares of Aclaris Therapeutics in the 2nd quarter valued at $2,120,000. Geode Capital Management LLC boosted its holdings in shares of Aclaris Therapeutics by 9.3% during the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock valued at $974,000 after acquiring an additional 72,309 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Aclaris Therapeutics during the 3rd quarter worth $1,053,000. 98.34% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Aclaris Therapeutics news, Director Anand Mehra bought 666,666 shares of the stock in a transaction on Tuesday, November 19th. The stock was purchased at an average price of $2.25 per share, with a total value of $1,499,998.50. Following the completion of the purchase, the director now owns 710,030 shares in the company, valued at $1,597,567.50. The trade was a 1,537.37 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 6.40% of the stock is currently owned by company insiders.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.